Victory Capital Management Inc. Cuts Holdings in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Victory Capital Management Inc. lessened its position in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) by 36.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 30,080 shares of the company’s stock after selling 17,080 shares during the period. Victory Capital Management Inc. owned approximately 0.06% of Tyra Biosciences worth $707,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new stake in shares of Tyra Biosciences during the 3rd quarter worth about $311,000. Perceptive Advisors LLC lifted its position in Tyra Biosciences by 50.5% during the second quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock valued at $16,108,000 after buying an additional 338,208 shares in the last quarter. Ally Bridge Group NY LLC acquired a new position in Tyra Biosciences during the second quarter valued at approximately $4,232,000. HighVista Strategies LLC purchased a new stake in Tyra Biosciences during the second quarter worth approximately $257,000. Finally, Ensign Peak Advisors Inc acquired a new stake in shares of Tyra Biosciences in the second quarter worth $3,047,000. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Tyra Biosciences Stock Performance

Shares of NASDAQ TYRA opened at $16.00 on Friday. Tyra Biosciences, Inc. has a 1 year low of $10.60 and a 1 year high of $29.60. The stock’s 50-day simple moving average is $20.43 and its 200-day simple moving average is $19.85. The firm has a market cap of $809.60 million, a price-to-earnings ratio of -9.94 and a beta of 1.08.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.01). As a group, research analysts predict that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.

Insider Activity at Tyra Biosciences

In other news, Director Nina S. Kjellson sold 11,078 shares of the stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $16.17, for a total transaction of $179,131.26. Following the transaction, the director now owns 472,207 shares of the company’s stock, valued at approximately $7,635,587.19. This trade represents a 2.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Todd Harris sold 10,092 shares of the business’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $24.13, for a total value of $243,519.96. Following the completion of the sale, the chief executive officer now directly owns 1,479,528 shares of the company’s stock, valued at approximately $35,701,010.64. This represents a 0.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 101,050 shares of company stock valued at $2,235,492 over the last ninety days. Corporate insiders own 15.40% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Wedbush restated an “outperform” rating and set a $28.00 target price on shares of Tyra Biosciences in a report on Friday, October 25th. Oppenheimer upped their target price on Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a research report on Thursday, September 19th. HC Wainwright lowered their target price on Tyra Biosciences from $32.00 to $30.00 and set a “buy” rating for the company in a research note on Monday, November 11th. Piper Sandler started coverage on Tyra Biosciences in a research report on Thursday, August 15th. They set an “overweight” rating and a $33.00 price target on the stock. Finally, Bank of America raised shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and increased their price objective for the company from $22.00 to $31.00 in a research report on Friday, October 18th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $31.00.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.